- Home
- LVLU vs XLO Comparison
LVLU vs XLO Comparison
Compare LVLU & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | XLO |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 56.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LVLU | XLO |
|---|---|---|
| Price | $10.79 | $9.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 47.4K | 9.2K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,284,000.00 | $43,766,000.00 |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $4.26 | $0.46 |
| 52 Week High | $32.32 | $9.90 |
Technical Indicators
Market Signals| Indicator | LVLU | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 48.64 |
| Support Level | $8.75 | $8.63 |
| Resistance Level | $12.76 | $9.15 |
| Average True Range (ATR) | 1.05 | 0.24 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 53.77 | 21.83 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates the majority of its revenue from customers based in the United States.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.